688513 Stock Overview
Chengdu Easton Biopharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Chengdu Easton Biopharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.69 |
| 52 Week High | CN¥46.84 |
| 52 Week Low | CN¥28.11 |
| Beta | 0.092 |
| 1 Month Change | -6.15% |
| 3 Month Change | -11.30% |
| 1 Year Change | -24.97% |
| 3 Year Change | -1.67% |
| 5 Year Change | n/a |
| Change since IPO | -39.62% |
Recent News & Updates
Concerns Surrounding Chengdu Easton Biopharmaceuticals' (SHSE:688513) Performance
Nov 01
There Is A Reason Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Price Is Undemanding
Jul 23Recent updates
Concerns Surrounding Chengdu Easton Biopharmaceuticals' (SHSE:688513) Performance
Nov 01There Is A Reason Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Price Is Undemanding
Jul 23Why Chengdu Easton Biopharmaceuticals' (SHSE:688513) Shaky Earnings Are Just The Beginning Of Its Problems
May 01Chengdu Easton Biopharmaceuticals Co., Ltd.'s (SHSE:688513) Share Price Matching Investor Opinion
Mar 26Shareholder Returns
| 688513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.9% | -1.0% | 0.4% |
| 1Y | -25.0% | -3.0% | 12.3% |
Return vs Industry: 688513 underperformed the CN Pharmaceuticals industry which returned -3% over the past year.
Return vs Market: 688513 underperformed the CN Market which returned 12.3% over the past year.
Price Volatility
| 688513 volatility | |
|---|---|
| 688513 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.8% |
Stable Share Price: 688513 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688513's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,481 | Mingxu Yuan | www.eastonpharma.cn |
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, cardiovascular, anesthetic/analgesics, anti-inflammatory, gastrointestinal, antiemetic, neurology/psychiatry, and urinary system therapeutic categories.
Chengdu Easton Biopharmaceuticals Co., Ltd. Fundamentals Summary
| 688513 fundamental statistics | |
|---|---|
| Market cap | CN¥5.33b |
| Earnings (TTM) | CN¥249.88m |
| Revenue (TTM) | CN¥1.31b |
21.4x
P/E Ratio4.1x
P/S RatioIs 688513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688513 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.31b |
| Cost of Revenue | CN¥300.48m |
| Gross Profit | CN¥1.01b |
| Other Expenses | CN¥756.92m |
| Earnings | CN¥249.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 77.02% |
| Net Profit Margin | 19.11% |
| Debt/Equity Ratio | 6.2% |
How did 688513 perform over the long term?
See historical performance and comparisonDividends
1.3%
Current Dividend Yield28%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 12:52 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chengdu Easton Biopharmaceuticals Co., Ltd. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Yin Ye | Ping An Securities Co. Ltd. |
| Tielin Chen | Topsperity Securities |